Article

Aptamer and ranibizumab safe, may be efficacious for subfoveal neovascular AMD

A phase I study of an intravitreal anti-platelet-derived growth factor (PDGF) aptamer (E10030, Ophthotech) that targets pericytes, evaluated in combination therapy with ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (AMD), indicated that the drug is safe and seems to have biologic activity against choroidal neovascularization (CNV), said David Boyer, MD, of Retina-Vitreous Associates, Beverly Hills.

Fort Lauderdale, FL-A phase I study of an intravitreal anti-platelet-derived growth factor (PDGF) aptamer (E10030, Ophthotech) that targets pericytes, evaluated in combination therapy with ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (AMD), indicated that the drug is safe and seems to have biologic activity against choroidal neovascularization (CNV), said David Boyer, MD, of Retina-Vitreous Associates, Beverly Hills.

“Ranibizumab is the gold standard and has provided great benefit to patients, but despite improvements in vision, CNV still grows, as seen in several trials,” added Dr. Boyer, speaking for the Ophthotech Study Group. “We may be able to improve vision by reducing the size of the CNV.”

The hallmark of maturation is the presence of pericytes. The aptamer targets PDGF, which controls pericytes and regulates vascular maturation.

Twenty-two patients were enrolled in the dose-escalating, uncontrolled, single- and multiple-dose, multicenter phase 1 study. The patients had predominantly or minimally classic subfoveal neovascular AMD 5 disc areas or less in total lesion size. Subjects received either one injection of 0.03 mg of the aptamer/eye and three monthly injections of ranibizumab 0.5 mg/eye (n = 3), or three monthly injections of one of four doses of the aptamer (0.03, 0.3, 1.5, or 3 mg/eye) and ranibizumab (0.5 mg/eye) (n = 3-8/doses). The end point was the presence of a dose-limiting response; the results were evaluated at 12 weeks, Dr. Boyer said.

At week 12, 60% of patients had a three-line gain in visual acuity (VA) and decreased central foveal thickness. An early increase in VA at 4 weeks was maintained at 12 weeks as was the decrease in CNV. There was 86% regression of neovascularization, according to Dr. Boyer.

The results indicated that the aptamer, combined with ranibizumab in patients with subfoveal neovascular AMD, was well tolerated.

“This PDGF therapy inhibits pericyte recruitment, strips pericytes in mature new vessels, induces regression in models of anti-VEGF therapy, enhances inhibition of new vessels when used with anti-VEGF therapy, and showed potential bioactivity,” Dr. Boyer concluded. “Another confirmatory trial is warranted.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.